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SARS Patients and
Need for Treatment 
To the Editor: We read with inter-
est the case report by Wong et al. (1).
Three similar cases of serologically
confirmed severe acute respiratory
syndrome (SARS) were treated in our
hospital; all of the patients recovered
uneventfully without specific treat-
ment. They had either negative results
on polymerase chain reaction (PCR)
tests for SARS-associated coronavirus
(SAR-CoV), or they were admitted
when such rapid diagnostic tests were
not yet available; hence, SARS-specif-
ic treatment was not prescribed.
The first patient was a 35-year-old
previously healthy female tourist
from Guangzhou, China, who was
admitted to our hospital in late
February 2003. She had visited sever-
al family members who had atypical
pneumonia; some eventually died
from the disease. The patient had
fever, chills, and dry cough approxi-
mately l week after exposure but
experienced no mylagia, diarrhea, or
shortness of breath. On physical
examination, scanty crepitations were
heard in her right lower chest, and
chest radiographs showed right lower
zone consolidation. Blood tests
showed a slightly low platelet count
of 119 x 109/L and mildly elevated
alanine transaminase at 59 U/L (nor-
mal <55 U/L), but total and differen-
tial leukocyte counts were normal.
Tests for etiologic agents included
blood and sputum bacterial cultures;
sputum for acid-fast bacilli; and
nasopharyngeal aspirates for influen-
za, parainfluenza, adenovirus, and
respiratory syncytical virus. Serologic
titers for Mycoplasma, Chlamydia
psittaci, and  Legionella were nega-
tive. Reverse transcription (RT)-PCR
tests for SARS-CoV were not avail-
able at that time.
Oral clarithromycin and intra-
venous amoxillin-clavulanate (subse-
quntly switched to levofloxacin) were
prescribed. Her high fever (tempera-
ture 39.5°C) lasted for 4 days and then
gradually subsided; the radiologic
abnormality also improved progres-
sively after the first week. Oxygen
supplementation of 2 L/min was nec-
essary for the first 2 days. The diagno-
sis of SARS was made when the
patient’s convalescent-phase serum
sample, collected 33 days after dis-
charge (day 45 of illness), showed an
elevated anti-SARS immunoglobulin
(Ig) G titer of 1:800 by immunofluo-
rescence.
The second patient was a 34-year-
old previously healthy man; his father
had shared a hospital cubicle with a
patient who was subsequently diag-
nosed with SARS. Fever (temperature
39°C), chills, and rigors developed in
patient 2 on December 3, 2003,
approximately 4 days after his first
hospital visit to his father; he had no
cough or gastrointestinal symptoms.
Chest radiographs showed right lower
zone consolidation. Blood tests
showed low platelet count of 91 x
109/L, elevated creatinine kinase (370
U/L), and elevated lactate dehydroge-
nase levels (1,060 U/L). Total and dif-
ferential leukocyte counts were nor-
mal. Tests for etiologic agents of pneu-
monia had negative results. His fever
(the highest temperature was 39.5°C)
subsided after day 2 of admission,
with a transient spike on day 11 that
coincided with a slight increase in
right lower zone consolidation. Both
abnormalities subsequently resolved
promptly, and no oxygen supplement
was necessary. RT-PCR test for
SARS-CoV was not available in our
hospital when he was admitted.
However, SARS was diagnosed when
his convalescent-phase serum, collect-
ed on day 21 of illness, demonstrated a
SARS-CoV IgG titer (by immuno-
fluorescence) of 1:3,200, from an ini-
tial baseline of <1:25, taken on day 12
of his illness. No treatment was given,
since the patient had already fully
recovered when the results arrived. 
The last patient was a 74-year-old,
previously healthy man, who had vis-
ited a sick relative; the relative was
later diagnosed with SARS. Fever,
chills, and cough developed in our
patient 4 days later. Chest radiograph
showed left lower and middle zone
consolidations. Intravenous ceftriax-
one and oral clarithromycin were
started. Blood tests showed elevated
alkaline phosphatase of 226 U/L and
alanine transaminase of 126 U/L. His
initial leukocyte count was 18.8 x
109/L with neutrophilia (16 x 109/L,
85.2%) and a normal lymphocyte
count of 1.2 x 109/L; platelet count
was normal. No causative agent was
identified, including by RT-PCR test
for SARS-CoV. His fever had sub-
sided upon admission, and serial chest
radiographs, liver function, and
leukocyte counts showed progressive
improvement without specific treat-
ment. The diagnosis of SARS was
made from two elevated SARS-CoV
IgG levels of both 1:3,200 (by
immunofluorescence), taken at days 5
and 24 after his admission (days 19
and 38 of illness).
Although SARS was diagnosed in
these three patients retrospectively,
and they were not treated with antivi-
ral agents, they were managed in iso-
lation wards. Patients reported adher-
ing to droplet precautions after dis-
charge (mainly, wearing surgical face
masks when in close contact with oth-
ers), and none was believed to have
transmitted the virus to others. 
SARS can be associated with a
substantial death rate (2). Ribavirin
and systemic corticosteroids were
used in our hospital during the SARS
epidemic. However, the efficacy of
this regimen has not been proven, and
concerns exist about side effects of
both drugs (3,4). Some retrospective
analyses suggested using lopinavir/
ritonavir and integrative Chinese and
Western medicine were associated
with improved outcomes (5,6). In
vitro (7,8) and animal (9) studies have
suggested that interferon and mono-
clonal antibodies might have some
effects on the disease. However, dataLETTERS
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from randomized controlled trials are
lacking. All of our patients had been
previously healthy, with no coexisting
conditions identified as poor prognos-
tic risk factors (2,10). These three
cases, together with the case of Wong
et al. (1), suggested that at least a sub-
set of SARS adult patients can have a
relatively benign clinical course and
uneventful recovery, without any spe-
cific treatment other than antimicro-
bial agents. 
Johnny W. M. Chan* 
and Samuel Lee*
*Queen Elizabeth Hospital, Hong Kong
Special Administrative Region, People’s
Republic of China
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To the Editor: A 24-year-old
female nurse was admitted to the
emergency room at Bichat University
Hospital in Paris, France, on July 4,
2001, with fever, nausea, and general
malaise. She had no notable medical
history, except spontaneously regres-
sive Schönlein-Henloch purpura at 9
months of age. On admission, after
she was given paracetamol, her axil-
lary temperature was 37.6°C. She was
slightly jaundiced and reported a mild
headache but showed no resistance to
head flexion. Her abdomen was
depressible but tender. Urinalysis did
not show hematuria or signs of uri-
nary infection. Biologic tests indicat-
ed normal values except the follow-
ing: platelets 47.4 x 103/µL, aspartate
aminotransferase 307 U/L (normal
value <56), alanine aminotransferase
239 U/L (normal value <56), total
bilirubin 58 µmol/L (normal value
<24), and γ-glutamyl transpeptidase
57 U/L(normal value <35). Results of
an abdominal echogram were normal.
Result of a blood film to identify
Plasmodium falciparum was positive
for parasitemia at 0.038 per 100 ery-
throcytes. The patient was given 500
mg of oral quinine three times daily;
intravenous quinine was administered
15 hours after admission because she
became nauseated. Her malaise per-
sisted for 3 days, but she did not show
any signs of malaria. She recovered
completely and was discharged on
day 6 of hospitalization. 
The patient had not traveled out-
side France except to the United
Kingdom years earlier. She did not
live near an airport, nor had she been
to one recently. She had vacationed in
the south of France from June 23 to
June 26 but had traveled by car. She
had been certified as a registered
nurse on May 28 and had been work-
ing as a substitute employee at vari-
ous hospitals in the greater Paris area.
On June 21, 2001, she sustained an
accidental needlestick injury while
taking a blood sample with an
18-gauge, peripheral venous catheter
that had no safety feature. She
removed the catheter stylet and stuck
herself as she crossed her hands to
discard the stylet in a sharps contain-
er. The needlestick pierced the nurse’s
glove and caused a deep, blood-let-
ting injury on the anterior aspect of
the left wrist. She had no previous
history of needlestick injury. She
notified the hospital occupational
medicine department of her injury on
the day it occurred and was given a
postexposure interview. In accor-
dance with national postexposure
management guidelines, she was test-
ed for HIV and hepatitis C virus
(HCV) antibody, and results were
negative at baseline; her immuniza-
tion against hepatitis B virus (HBV)
was confirmed. The risk of infection
by pathogens other than HBV, HCV,
or HIV following a needlestick injury
was not discussed during her postex-
posure interview, and the nurse was
not made aware of that risk. The
injured nurse did not inform the man-
aging physician that the injury had
occurred while she was drawing